P450-BM3 VARIANTS WITH IMPROVED ACTIVITY

1 . An engineered cytochrome P450-BM3 variant comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 36, 4, 66, 72, 198, 226, 244, 286, 358, 410, 534, 734, 748, 828, 968, 984, 1160, or 1266, or a functional fragment thereof, wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 36, 4, 66, 72, 198, 226, 244, 286, 358, 410, 534, 734, 748, 828, 968, 984, 1160, or 1266.

2 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 4, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 52/83/88/105, 32/83/88, 32/83/88/176, 32/83/88/231/574, 32/83/88/574, 52/83/88, 52/83/88/231, 52/83/88/231/433/574, 52/83/88/433, 52/83/88/433/574, 52/83/88/574, 83/88, 83/88/105, 83/88/111, 83/88/111/433, 83/88/111/574, 83/88/231, 83/88/349, 83/88/433/574, and 83/88/574, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 4.

3 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 36, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 75, 75/374, 75/374/458/726, 75/374/726, 75/458, 75/458/726, 75/726, 111/114, 111/603/604/623/853, 111/623, 374/726, and 726, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 36.

4 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 66, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 74, 75, 83, 179, 181, 182, 186, 189, 238, 267, 268, 328, 331, 355, 358, 437, and 438, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 66.

5 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 72, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 74/75/83/179/189/328/331/437, 74/75/268/328/331/358/437, 74/83/268/328/331/358/437, 74/267/268/328, 75/83/179/189/331, 75/83/179/268/328/331/437, 75/83/189/267/268, 75/83/267/268/355/358/654, 75/83/268/437, 75/268/328/331/358, 83/179/182/437, 83/179/189/331/355, 83/179/328/331, 83/179/355/358/437, 83/182/189/268/328/331/355/358/437, 83/182/189/328/331, 83/182/268/328/355/358/437, 83/189/267/268/358, 83/189/268/328/331, 83/189/268/328/355/358/437, 83/189/328/331/437, 83/267/268/328/331/355/358, 83/268, 83/268/328/331, 83/268/328/331/355/358, 83/268/328/331/358, 83/268/328/331/358/437, 83/268/328/331/437, 83/268/331, 83/331, 83/331/437, 83/358/437, 179/182/268, 179/189/331/437, 179/328/331, 179/331/358, 189/267/268/437, 189/268/328, 189/268/328/331/358/437, 189/268/358, 267/268/328, 267/268/328/331/355/358, 267/268/331/355/358/437, 268, 268/328/331, 268/328/355/358, 268/331/355/358, 268/355/358/437, 268/358, and 328/331/358, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 72.

6 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 198, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 79, 213, and 257, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 198.

7 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 226, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 315, 320, 385, 388, 391, 398, 405, 493, 497, 502, 503, 504, 541, 542, 547, 573, 576, and 577, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 226.

8 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 244, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 75/178/213/315, 75/331/576/726, 178, 178/179/213/437/497/573/576, 178/179/573/726, 178/179/576, 178/213/573, 178/213/726, 178/437, 178/497/726, 178/576, 178/726, 179/358, 179/726, 331, 331/358/391/437, 331/497, 331/573/576, 497/573, 573, 682, 685, 699, 701, 704, 707, 708, 726, 756, 759, 794, 796, 797, 848, 851, 862, 888, 889, 999, 1003, and 1048, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 244.

9 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 286, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 75/331/701/726/851/1048, 75/331/726/999, 75/726/796/851/999, 75/1048, 87, 88/522, 89, 234, 269, 328, 330, 331, 398, 405, 408, and 411, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 286.

10 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 358, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 77, 170, 286, 289, 462, 547, 557, 630, 646, 651, 672, 676, 692, 775, 786, 787, 788, 814, 841, 876, 877, 888, 893, 896, 924, 941, 955, 969, 973, 982, 989, 993, 1038, 75/269/707, 269, 269/522/707, 269/522/707/1048, 522, 522/726, 522/1048, and 726/1048, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 358.

11 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 410, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 158/170, 158/170/410/462/630/672/726/786/788/814/924, 158/170/410/462/726/786/814, 158/170/410/924, 158/170/630/726/786/788/814, 158/410, 158/410/462/557/969, 158/410/557/786/787, 158/410/814/924, 158/410/862, 158/462/557/630/924, 158/462/630/786/788/969, 158/557, 158/557/630/814, 158/557/726/786/788/862, 158/557/786, 158/557/786/787/788, 158/557/814/924, 158/630/786/814, 158/726, 158/786/787/788, 158/814/924, 170/410/557/786/787/814/924/989, 385, 410/462/557/630/786/787/969, 462/557/726/786/787/924, 469, 523, 550, 553, 556, 574, 613, 640, 645, 650, 652, 717, 773, 779, 795, 838, 871, 923, 926, 51/851, 460, 466, 474, 597, 600, 635, 638, 655, 663, 664, 677, 694, 696, 713, 771, 783, 789, 806, 807, 840, 842, 851, 857, 860, 878, 894, 942, 947, 960, 978, 992, 1008, 1012, 1024, and 1025, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 410.

12 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 544, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 77/179/286/410/788/888, 77/410/676/788/924, 77/557/707/888, 286/410/651/676, 286/410/707/788, 286/410/888, 286/692/786/788, 410, 410/557/676/788/888/924/993, 410/557/692/788, and 410/646/651/788, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 544.

13 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 734, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 24, 53, 75, 78, 82, 88, 150, 180, 183, 257, 270, 410/497/557/576/814, 410/497/573/576, 410/497/814, 410/557/924, 437, and 497/557, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 734.

14 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 748, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 75, 75/82/180/257/437, 75/82/257/268, 75/82/257/556/640, 75/82/257/773, 75/82/437, 75/180/183/257/268/270/385/437/556/613/652/923, 75/180/257/268/270/437/556/574/652, 75/180/574/795, 75/257/613, 75/257/640, 75/556/773, 75/574, 75/613, 82/613, 180/437/773/795, 257/613/773/795, 45, 102, 106, 110, 111, 114, 127, 191, 193, 194, 196, 196/853, 198, 202, 203, 206, 210, 226, 232, 236, 237, 244, 245, 248, 254, 256, and 347, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 748.

15 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 828, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 22/75/717/720/779/1004, 22/550/826, 22/616/717/1004, 22/717/795/799/826, 550/616/717/779, 550/640/717, 550/717/795/799/800, 616/717/720/799, 640, 717, 717/720/779/1004, 717/779/799/800/1004, 717/1004, 720/779, 779/1004, 800/1004, and 826/1004, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 828.

16 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 968, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 3, 118/446, 132, 230, 285, 290, 292, 293, 295, 296, 300, 303, 305, 307, 366, 371, 372, 381, 382, 415, 417, 418, 424, 427, 432, 433, 446, 447, 455, 463, 465, 468, 473, 473/790, 478, 480, 481, 506, 600/635/713/771/1025, 600/840/960, 635/636/793/840, 635/638/793/823/960, 635/713/1025, 635/771/894, 636/638/793/851, 638/663/793/840, 713, 771, 786/840/960, 793/840, 807, 840/960, 851/1024/1025, 851/1025, 960, and 1025, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 968.

17 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 984, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 45, 45/111/226/347, 45/853, 110/114, 111, 111/127/226/244, 111/194/244/347/853, 111/194/347, 111/194/347/853, 111/210, 111/210/347/853, 111/226, 111/226/244/347, 111/226/853/969, 111/244, 111/244/853, 111/347/853, 111/853, 114, 114/245, 127/210/244, 127/210/244/853, 127/210/347/853, 127/244, 127/347, 194/853, 210/853, 226/236/244/347/853, 236/244, 237, 237/245, 244/853, 245, 518, 518/652, 519, 562, 563, 584/724, 586, 616, 618, 619, 621, 623, 628, 640, 653, and 666 wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 984.

18 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1160, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 132/366/433/463/467/793, 132/366/467/661, 132/467/468/506/793, 132/468/793, 132/1025, 183/1025/1045/1048, 290/366/433/463/467, 290/433/467/793/1025, 290/433/793, 290/793, 290/1025, 366/433, 433, 433/467/1025, 433/506/1025, 433/790, 463/793, 473, 793, and 1025, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1160.

19 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1266, and wherein the polypeptide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 114/230/446/853, 114/292/293/296/463/853, 132/183/366/467/661/1025/1045/1048, 132/290/366/433/467/661/793/1025, 132/290/366/467/661/793, 132/290/366/467/661/1025, 132/366/433/467/506/661/1025, 132/366/433/467/661, 132/366/433/467/661/790, 132/366/463/467/661/793, 132/366/467/473/661, 132/366/467/661/793, 366/467/468/506/661/793, 433/463/467/661/793, 463, 463/853, 689, 720, 724, 730, 769, 780, 792, 810, 817, 824, 853, 923, 926, 939, 952, 962, 968, 974, 979, 981, 995, 1006, 1015, 1017, 1022, 1027, 1031, 1040, 458, 518/653, 519/628, 616/619, and 653 wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1266.

20 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said engineered cytochrome P450-BM3 variant comprises a polypeptide sequence selected from the group consisting of (a) a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 4, 36, 66, 72, 198, 226, 244, 286, 358, 410, 534, 734, 748, 828, 968, 984, 1160, or 1266;

(b) a polypeptide sequence set forth in SEQ ID NO: 36, 66, 72, 198, 226, 244, 286, 358, 410, 534, 734, 748, 828, 968, 984, 1160, or 1266; and

(c) a polypeptide sequence forth in at least one of the even numbered sequences of SEQ ID NOS: 4-1368.

21 . The engineered cytochrome P450-BM3 variant of claim 1 , wherein said engineered cytochrome P450-BM3 variant comprises at least one improved property, as compared to a wild-type Bacillus megaterium cytochrome P450-BM3 or engineered P450-BM3 variant.

22 . The engineered cytochrome P450-BM3 variant of claim 21 , wherein said improved property comprises a property selected from the properties consisting of (a) an improved activity on a substrate, (b) improved thermostability, (c) increased activity on a substrate after preincubation at 42.5° C. and (d) improved stereoselectivity toward one or more diastereomer products.

23 . The engineered cytochrome P450-BM3 variant of claim 22 , wherein said substrate comprises 1-tert-Butoxycarbonylaminocyclopentanoic acid (Compound (1)).

24 . A polynucleotide sequence encoding at least one engineered cytochrome P450-BM3 variant of claim 20 , said polynucleotide sequence comprises at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NOS: 3, 35, 65, 71, 197, 225, 243, 285, 357, 409, 533, 733, 747, 827, 967, 983, 1159, or 1265, wherein the polynucleotide sequence of said engineered cytochrome P450-BM3 variant comprises at least one substitution at one or more positions.

25 . An expression vector comprising at least one polynucleotide sequence of claim 24 .

26 . A host cell comprising at least one polynucleotide sequence of claim 24 .

27 . A method of producing an engineered cytochrome P450-BM3 variant in a host cell, comprising culturing a host cell of claim 26 , under suitable conditions, such that at least one engineered cytochrome P450-BM3 variant is produced.